Neuphoria Therapeutics Inc.

What they do

Neuphoria is a clinical-stage biopharmaceutical company focused on neuropsychiatric disorders. Its lead candidate, BNC210, is an oral negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor, in Phase 3 for social anxiety disorder (SAD) and Phase 2b for PTSD. The company also has a strategic partnership with Merck for two early-stage Alzheimer's/CNS candidates and preclinical programs targeting the alpha-7 receptor and Kv3.1/3.2.

Revenue drivers

• No approved products — The company has no approved products and generates no product revenue. Annual revenue was $15.6M in 2025, primarily from collaboration or licensing agreements.
• Merck partnership — Strategic partnership with Merck for two early-stage clinical candidates for cognitive deficits in Alzheimer's and other CNS conditions. This is a source of collaboration revenue.
• Collaboration revenue — Revenue appears to come from upfront payments, milestones, or research support from partnerships. No product sales are generated.

Recent performance

In Q1 2026 (quarter ended March 31, 2026), the company reported revenue of $15.0 million, a significant increase from $662,715 in Q4 2024. It reported a net loss of $400,000 for fiscal 2025, improving from net losses of $21.4M (2023) and $15.5M (2024). Operating cash flow was positive $77,229 in 2025 after being negative ~$14.6M and ~$14.7M in 2023 and 2024. As of March 31, 2026, the company had $19.4M in cash and equivalents, total assets of $34.8M, and shareholder equity of $29.4M.

Strategy

The company is advancing BNC210 into Phase 3 clinical trials for SAD, with AFFIRM-1 as the first of two pivotal trials needed for an NDA. Management plans to initiate AFFIRM-2 in the first half of 2026, contingent on positive AFFIRM-1 results and sufficient capital. The company is also continuing development of its PTSD program and preclinical pipeline, while leveraging the Merck partnership for early-stage CNS assets.

Risks

• No approved products — Neuphoria has no approved products and expects significant operating losses for the foreseeable future, with no guarantee of revenue or profitability.
• Phase 3 execution risk — BNC210's Phase 3 AFFIRM-1 trial is ongoing; if it fails, the company may be unable to advance to AFFIRM-2 or secure regulatory approval.
• Capital constraints — With only $19.4M in cash as of March 31, 2026, the company may need additional capital to fund ongoing trials and operations.
• Listing compliance — The company received delisting notices in December 2025 and September 2025, indicating potential Nasdaq listing-rule compliance issues.

Outlook

Management expects topline results from the Phase 3 AFFIRM-1 trial early in Q4 2025, and plans to initiate AFFIRM-2 in the first half of 2026, subject to positive results and capital availability. The company is also a clinical-stage company with no approved products, and its future depends on successful trial outcomes and regulatory approvals.